Company intelligence / Profile preview

Glycologix

Boston, Massachusetts, USAglycologix.com ↗

Ownership: Private
Employees: ~9
Development stage: Phase 1

Overview

Glycologix’s lead program, GLX‑100, is a locally delivered chondroitin sulfate-based biopolymer for interstitial cystitis/bladder pain syndrome. The company’s technology platform is designed to mimic the structure and function of natural proteoglycans to restore hydration, lubrication, and structural support in soft tissues. The platform has potential applications across multiple large unmet medical needs; however, detailed clinical results have not been publicly disclosed as of June 2025.

Therapeutic areas: NephrologyOtherDermatologyRheumatologyOphthalmologyNeurology
Modalities: BiopolymerSynthetic proteoglycan mimicChondroitin sulfate-based biopolymerBiomaterial therapy (locally delivered)
Industry: Biotech

Drug pipeline

1 asset

GLX-100

Unknown

Beyond the preview

Go deeper on Glycologix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycologix.

Explore the full profile